New catalytic strategy delivers chiral three-dimensional molecular scaffolds for future medicines

Medicinal chemists are increasingly exploring saturated, three-dimensional bioisosteres as alternatives to planar aromatic heterocycles to improve the physicochemical and pharmacological properties of drug candidates. Among these emerging molecular frameworks, 3-azabicyclo[3.1.1]heptanes (3-aza-BCHeps) have attracted growing interest as potential pyridine bioisosteres. However, catalytic enantioselective methods for accessing these chiral nitrogen-bridged scaffolds have remained scarce. Researchers have now developed a chiral Brønsted acid-catalyzed asymmetric transfer hydrogenation that provides efficient access to enantioenriched 3-aza-BCHeps with broad substrate scope and excellent enantioselectivity.

Researchers have now reported an efficient catalytic strategy that provides straightforward access to one of these highly sought-after molecular architectures—enantioenriched 3-azabicyclo[3.1.1]heptanes (3-aza-BCHeps)—using a chiral Brønsted acid catalyst under operationally simple conditions. The work offers a practical platform for preparing three-dimensional, sp³-rich heterocycles that could serve as valuable scaffolds for drug discovery and asymmetric synthesis.

The new method employs asymmetric transfer hydrogenation, using a readily available Hantzsch ester as the hydride donor together with a chiral Brønsted acid catalyst. The reaction efficiently converts readily accessible bicyclic imine substrates into structurally diverse 3-aza-BCHeps in generally high yields while achieving excellent enantioselectivities. The broad substrate scope further demonstrates the robustness and synthetic practicality of the protocol.

Unlike many existing approaches that require multiple synthetic steps or offer limited stereochemical control, the newly developed catalytic system provides direct access to enantiomerically enriched bridged nitrogen heterocycles under relatively mild conditions. The authors propose that the remarkable stereoselectivity arises from a well-defined network of non-covalent interactions that governs hydride transfer during the catalytic process.

Beyond efficient synthesis, the study demonstrates the versatility of the resulting molecular framework. The chiral 3-aza-BCHeps can undergo stereospecific nitrogen deletion to furnish bicyclo[2.1.1]hexanes while completely retaining enantiopurity. This stereospecific transformation further expands the synthetic utility of the method by enabling straightforward access to enantioenriched bicyclo[2.1.1]hexanes.

The researchers also showed that the newly synthesized 3-aza-BCHeps are more than synthetic intermediates. They can serve as a new class of chiral secondary amine organocatalysts, successfully promoting asymmetric Friedel–Crafts alkylation reactions with excellent yields and promising stereoinduction. This dual role—as both target molecules and functional catalysts—highlights the broader impact of the work for asymmetric synthesis.

The strategy contributes to the growing movement toward designing three-dimensional, C(sp³)-rich molecules, an increasingly important direction in modern medicinal chemistry. Such three-dimensional, C(sp³)-rich molecular frameworks have attracted increasing attention in medicinal chemistry because they can offer attractive alternatives to planar heteroaromatic motifs.

Overall, this study establishes a practical, step-economical route to an important class of chiral saturated heterocycles. By combining operational simplicity, broad substrate scope, exceptional enantioselectivity, and versatile downstream transformations, the methodology provides researchers with a powerful new tool for constructing complex molecular architectures that may provide new opportunities for medicinal chemistry and asymmetric catalyst development.

About the research

The reported methodology is based on a chiral Brønsted acid-catalyzed asymmetric transfer hydrogenation of bicyclic imines using Hantzsch ester as the hydride donor. The reaction furnishes diverse enantioenriched 3-azabicyclo[3.1.1]heptanes under relatively mild with excellent enantioselectivities. The resulting products can be converted into bicyclo[2.1.1]hexanes without loss of enantiopurity and further serve as a new class of chiral organocatalysts, demonstrating their value as versatile chiral building blocks for medicinal chemistry and asymmetric catalysis.